L’Oreal is worth more than LVMH. Beauty just took France’s market crown.

L'Oreal ended Tuesday worth about €203 billion. LVMH ended at €201 billion, according to London Stock Exchange Group (LSEG) data reported by Reuters. It is the first time since 2017 that France's most valuable listed company has not been a luxury group. The paths crossed slowly, then all at once. L'Oreal shares are up 5% this year. LVMH is down 35%, after a luxury slowdown in China and years of price rises. Bain estimates that about 60 million consumers have left the luxury market since 2022.

In August, we wrote that affluent Chinese shoppers were choosing a repeatable serum over a deferrable handbag. The stock market has now priced that trade across two companies. Beauty did not beat luxury by becoming cheap. It won by offering a smaller ticket that runs out. There is an important wrinkle. L'Oreal owns Lancôme, Yves Saint Laurent Beauté and other licensed luxury beauty businesses. The new market crown is not mass beating prestige. It is replenishment beating the trophy purchase. LVMH's first-half numbers made the split visible. Perfumes and cosmetics sales were flat on an organic basis. Selective retailing, the division that contains Sephora, grew 5%. LVMH said Sephora sustained organic growth but did not give the chain its own rate. L'Oreal wins the headline. Retailers and consumable categories win the structure. Watch the two market values at year-end. A one-day crossover is symbolism; six months would be a repricing of what luxury means.

A-Frame Brands built Loved01, Kinlò and Proudly with celebrity partners. It is now redirecting that machinery toward private-label brands owned by retailers. The company says three large US retailers are already clients. Bath & Body Works used it for limited-edition skincare and pet-care lines. A-Frame is also developing a Gen Alpha brand for an unnamed beauty retailer. CEO Ari Bloom says about 80% of its retailer conversations concern categories the client has not built itself.

This changes which risk A-Frame keeps. Under its old model, it formed companies around brands, split ownership with talent and carried the costs of selling through retailers. Private label lets it sell formulation, sourcing and marketing without owning or scaling the finished brand. In August, four celebrities filed beauty trademarks before announcing brands. We called the filing the cheapest possible demand test. A-Frame is moving one step further: the famous name becomes optional, while the retailer's traffic, data and margin become the product brief. The economics explain it. US private-label sales across categories reached $282.8 billion in 2025, according to data cited by the Private Label Manufacturers Association. A-Frame says its own celebrity brands remain in operation, but their physical footprints have narrowed. Retailers win by renting a brand team instead of building one. A celebrity label loses its easy advantage when the retailer itself is the name shoppers know. Watch which of A-Frame's three clients puts its name on the first permanent line.

Ju Rhyu sold Hero Cosmetics to Church & Dwight for $630 million after making pimple patches ordinary in America. Her second brand starts with another Korean beauty translation: daily facial sunscreen. Vize goes direct on 22 September. Its only product is a $24, 50-milliliter SPF 30. Rhyu and dermatologist Aimee Paik put about $1 million of their own money into it. Rhyu says outside funding can wait until sales reach $10 million. Amazon is expected next; a physical retailer waits until the range has about five products.

The formulation is inspired by Korean textures, but it is made for the old American filter set. Vize combines zinc oxide with an established organic UV filter. It does not use bemotrizinol, the new filter that reached the US monograph in August. Ultra Violette already used that regulatory opening to launch first. So Vize is not selling novelty in the filter. It is selling routine. The brand chose a September launch because sunscreen sales usually peak inside four months. Hello Sunday founder Amy Ford estimates that about 70% of category sales land from March through July. Price matters less than the refill interval. Paik estimates one bottle lasts about 45 days with daily use. A winter reorder would mean Vize changed behaviour; waiting until spring would leave it with another seasonal SKU. Watch the second-purchase rate in November and December. Hero taught shoppers a new format. Vize has to teach them a new calendar.

Cécred enters all 90 Space NK stores in the UK and Ireland on 22 September. It is Beyoncé's hair brand's first physical retail launch outside the United States. The UK is already its second-largest market, and the brand ships directly to consumers in 100 countries. Ulta announced the US partnership in February 2025. Cécred reached more than 1,400 US stores on 6 April in what Ulta called its largest exclusive hair-care brand launch. Cécred says it remains Ulta's top prestige hair brand, while YipitData ranks its Restoring Hair & Edge Drops as the category's leading product. The company declined to disclose revenue.

The retailer name changes at the border. The owner does not. Ulta bought Space NK last year, so this is the same distribution rail carrying Cécred into a market where demand already exists. We saw the mechanism twelve days ago with Touchland: an American Ulta brand crossed the Atlantic as a Space NK exclusive. Cécred is the second clear example in this archive. Ulta did not buy a British chain only for its current sales. It bought a landing strip. Cécred has done the expensive work first. It funded six years of development, built its own laboratory and test salon, then used direct shipping to locate demand before renting 90 shelves. That order reduces launch risk, even if celebrity attention helped create the map. Space NK wins an established audience. Ulta wins at both ends. Watch which US brand becomes the third passenger, and whether Cécred's UK sales move from online orders into repeat store visits.

Permanent hair colour forces pigment into the hair by oxidation. The paper says that chemistry may damage hair and scalp. It may also deplete the stem cells that make pigment, and set off allergies. Researchers at Rohto Pharmaceutical in Osaka, with colleagues at Kobe University, published a different route in the [International Journal of Cosmetic Science](https://doi.org/10.1111/ics.70145) on 11 September. They used 5,6-dihydroxyindole. It is what the body turns into the dark pigment in hair. On its own it takes poorly. So they coated the hair first with a positively charged polymer that holds its charge in alkali. The surface charge moved positive, and the pigment lodged in the cuticle and fixed itself there.

Read the authors before the result. Four of the eight work in the hair care development division of a company that sells hair care. The work is bench work, measured by instrument on hair samples rather than volunteers, and the paper offers it as a possible alternative. Our read is that the pressure behind it is regulatory. Europe keeps cutting its permitted ingredient lists, and hair colour is the oldest and most allergenic chemistry still sold at scale. A colour built from the body's own pigment precursor is hard to argue with. The incumbents selling oxidative dye have something to lose, and that is most of the aisle. Copying it will not be simple. The clever part is the polymer pretreatment, and that is what gets patented. Watch Rohto. A grey coverage product on this chemistry, on a Japanese shelf, by the end of 2027.

dsm-firmenich makes flavours, fragrance ingredients and nutrition products. On 14 September it said it has [partnered with Boltz](https://our-company.dsm-firmenich.com/en/our-company/news/trade-news/2026/dsm-firmenich-partners-with-boltz-on-ai-for-ingredient-discovery.html), a company founded by former Massachusetts Institute of Technology (MIT) scientists. Boltz builds AI models that predict how molecules bind to proteins. The target is smell and taste receptors. Those receptors are proteins, and working out which molecule fits which one is the problem drug discovery has been throwing AI at for years. dsm-firmenich is putting its own library of receptor data behind the models. What comes out is a set of models only it can use.

Look at what each side brings. Boltz has the models. Anyone with money can eventually license models. What dsm-firmenich has is decades of receptor data it calls unrivalled, and that is the half you cannot buy. Neither works alone, which is why the output is exclusive. Our read is that this is the picks and shovels layer again. In July we wrote about Givaudan buying into precision encapsulation. The argument then was that whoever owns how an active gets delivered sits underneath every brand downstream. Same shape here, one step earlier. The perfumer loses here, whatever the release says about freeing them up. Pattern recognition was the job. A model now does part of it. dsm-firmenich says it launched the world's first AI-created flavour back in 2020, so this is a scaling step rather than a beginning. Watch for the first commercial fragrance ingredient credited to this work before the end of 2027.